Ascentage Pharma Group International filed a Form F-1 registration statement for an initial public offering on 2024-12-27. It has amended it 1 time. It filed its final prospectus on 2025-01-24. Each fact below is quoted from the filing named with it.
What the filings say
Listing
The ADSs have been approved for listing on the Nasdaq Global Market, or Nasdaq, under the symbol “AAPG.” Application will be made to the HKEx for the listing of the ordinary shares represented by the ADSs we are offering, and we expect to obtain the approval of the HKEx before the ordinary shares are issued upon the closing of the offering.From the 424B4 filed 2025-01-24
Use of proceeds
We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows:From the 424B4 filed 2025-01-24
Revenue
For the nine months ended September 30, 2024, we generated revenue of RMB876.8 million (US$124.9 million) from intellectual property income, sales of pharmaceutical products and commercialization rights income, compared to RMB175.5 million for the nine months ended September 30, 2023, representing an increase of RMB701.3 million, or 400.0%, which was primarily attributable to intellectual property income of RMB678.4 million from Takeda and the increase in sales of pharmaceuticals products of RMB11.9 million.From the F-1/A filed 2025-01-21
Net loss or income
While our net profit was RMB162.8 million (US$22.4 million) for the six months ended June 30, 2024, our net loss was RMB402.3 million for the six months ended June 30, 2023, and we incurred a net loss of RMB925.7 million (US$127.4 million) and RMB882.9 million for the years ended December 31, 2023 and 2022, respectively.From the F-1/A filed 2025-01-21
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-12-27 | Registration statement filed (foreign issuer) | F-1 |
| 2025-01-21 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-01-24 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Ascentage Pharma Group International. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.